-
公开(公告)号：KR100879411B1
公开(公告)日：2009-01-19
申请号：KR1020060065840
申请日：2006-07-13
Applicant: (주)아모레퍼시픽 , 에스비사이언스(주)
IPC: A61K31/131 , A61P17/02
Abstract: 본 발명은 하기 화학식 1로 표시되는 2-아미노-2-옥틸옥시메틸-프로판-1,3-디올(2-amino-2-octyloxymethyl-propane-1,3-diol, AOOMP) 또는 이의 약학적으로 허용 가능한 염을 포함하는, 스핑고실포스포릴콜린(sphingosylphosphorylcholine, SPC)의 작용을 억제하는 약학 조성물에 관한 것이다.
본 발명에 따른 약학 조성물은 SPC의 생체내 및 생체외 작용에 따른 세포 분열 증식, 염증 반응, 히스타민 분비 또는 가려움증 등을 효과적으로 억제하고, 투여시 심장 박동수의 저하와 같은 부작용이 없으므로, 외상 후의 흉터 형성 억제 및 아토피성 피부염 또는 기타 질환에서 나타나는 염증, 소양증, 및 피부 감염증 등의 예방 및 치료에 유용하게 사용될 수 있다.-
公开(公告)号：KR1020080006737A
公开(公告)日：2008-01-17
申请号：KR1020060065840
申请日：2006-07-13
Applicant: (주)아모레퍼시픽 , 에스비사이언스(주)
IPC: A61K31/131 , A61P17/02
Abstract: A pharmaceutical composition is provided to effectively inhibit cell proliferation, inflammatory reaction, histamine secretion or itch caused by the function of sphingosylphosphorylcholine without side effects, thereby being usefully used for inhibiting scar formation after wound and preventing and treating inflammation, pruritus and skin inflammatory diseases. A pharmaceutical composition for inhibiting the function of sphingosylphosphorylcholine comprises 2-amino-2-octyloxymethyl-propane-1,3-diol represented by the formula(1) or a pharmaceutically acceptable salt thereof. The composition further comprises a carrier, an excipient or a diluent.
Abstract translation: 提供药物组合物以有效地抑制由鞘脂酰磷酰胆碱的功能引起的细胞增殖，炎症反应，组胺分泌或瘙痒，无副作用，从而有效地用于抑制伤口后的瘢痕形成，预防和治疗炎症，瘙痒和皮肤炎症性疾病。 用于抑制鞘糖基磷酰胆碱功能的药物组合物包含由式（1）表示的2-氨基-2-辛氧基甲基 - 丙烷-1,3-二醇或其药学上可接受的盐。 组合物还包含载体，赋形剂或稀释剂。
-
公开(公告)号：KR100643512B1
公开(公告)日：2006-11-10
申请号：KR1020040089799
申请日：2004-11-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/202 , A61K31/5575
CPC classification number: A61K31/202
Abstract: 본 발명은 아라키돈산 대사물질 또는 그 유도체의 용도에 관한 것으로서, 보다 상세하게는 아라키돈산 대사물질인 12(s)-HPETE, 15(s)-HPETE 또는 그 유도체의 투여량을 조절하여 동물에서 가려움증을 유발하는 방법, 가려움증 억제 물질의 스크리닝 방법 및 그 스크리닝한 가려움증 억제 물질의 약효를 평가하는 방법에 관한 것이다. 본 발명에 의한 아라키돈산 대사물질 또는 그 유도체는 가려움증을 이해하고 연구하는데 유용하며, 이를 바탕으로 가려움증 치료 약을 검색하거나 약효를 평가하여 개발하는데 매우 유용하게 사용될 수 있다.
아라키돈산 대사물질, 12(s)-HPETE, 15(s)-HPETE, 가려움증 억제 물질, 가려움증-
公开(公告)号：KR101055108B1
公开(公告)日：2011-08-08
申请号：KR1020100080997
申请日：2010-08-20
Applicant: (주)아모레퍼시픽
IPC: A61K36/254 , A61K36/74 , A61P17/00
Abstract: 본 발명은 생약재 추출물을 함유하는 피부 외용제 조성물에 관한 것으로, 더욱 상세하게는, 가시오가피(
Acanthopanacis
Cortex ), 강진향(
Dalbergiae
odoriferae
Lignum ), 노근(
Phragmitis
Rhizoma ), 당귀(
Angelicae
Gigantis
Radix ), 백자인(
Thujae
Semen ), 백질려(
Tribuli
Semen ), 백출(
Atractylodis
Rhizoma
alba ), 봉출(
Zedoariae
Rhizoma ), 부평초(
Spirodelae
Herba ), 사상자(
Torilidis
Fructus ) 및 석곡(
Dendrobii
Herba ) 중에서 선택된 1종 이상의 추출물을 함유하는 피부 외용제로서, T 임파구 매개성 면역반응 억제능력에 의해 아토피성 피부염, 접촉성 피부염, 건선 등의 피부질환을 치료 또는 예방하기 위해 사용될 수 있다.Abstract translation: 本发明涉及含有草药提取物的皮肤外用组合物，更具体地说，
-
公开(公告)号：KR1020100097648A
公开(公告)日：2010-09-03
申请号：KR1020100080997
申请日：2010-08-20
Applicant: (주)아모레퍼시픽
IPC: A61K36/254 , A61K36/74 , A61P17/00
Abstract: PURPOSE: An external use skin composition containing herb extract is provided to suppress T lymphocyte-mediated immune reaction and to prevent or treat atopic dermatitis, contact dermatitis, and psoriasis. CONSTITUTION: A cosmetic composition for treating T lymphocyte-mediated dermal immune diseases contains 0.001-10 weight% of Thujae Semen extract as an active ingredient. A method for producing the Thujae Semen extract comprises: a step of pulverizing Thujae Semen and adding 95% of ethanol; a step of heating at 80°C for 2 hours to extract active ingredient; a precipitating impurities and filtering; and a step of evaporating. A pharmaceutical composition for treating T lymphocyte-mediated dermal immune diseases contains Thujae Semen extract as an active ingredient.
Abstract translation: 目的：提供含有草药提取物的外用皮肤组合物，以抑制T淋巴细胞介导的免疫反应，预防或治疗特应性皮炎，接触性皮炎和牛皮癣。 构成：用于治疗T淋巴细胞介导的真皮免疫疾病的化妆品组合物含有0.001-10重量％的Thujae Semen提取物作为活性成分。 一种Thujae Semen提取物的制造方法，其特征在于，包括：将Thujae Semen粉碎并加入95％乙醇的步骤; 在80℃下加热2小时以提取活性成分的步骤; 沉淀杂质和过滤; 和蒸发的步骤。 用于治疗T淋巴细胞介导的真皮免疫疾病的药物组合物含有Thujae Semen提取物作为活性成分。
-
Patent Agency Ranking
公开(公告)号：KR1020100031117A
公开(公告)日：2010-03-19
申请号：KR1020100011764
申请日：2010-02-09
Applicant: (주)아모레퍼시픽
Abstract: PURPOSE: A composition of a skin external agent is provided to treat and prevent various dermatitis caused by T lymphocyte-mediated immune response. CONSTITUTION: A cosmetic composition for relieving dermatitis caused by T lymphocyte-mediated immune response contains Dalbergiae odoriferae lignum extract as an active ingredient. The dermatitis includes atopic dermatitis, contact dermatitis or psoriasis. The composition contains 0.001-10 weight% of Dalbergiae odoriferae lignum extract based on total weight.
Abstract translation: 目的：提供皮肤外用剂的组合物，以治疗和预防由T淋巴细胞介导的免疫应答引起的各种皮炎。 构成：用于缓解由T淋巴细胞介导的免疫应答引起的皮炎的化妆品组合物含有檀香木提取物作为活性成分。 皮炎包括特应性皮炎，接触性皮炎或牛皮癣。 该组合物含有0.001-10重量％的总重量的檀香木提取物。
-
公开(公告)号：KR1020100021641A
公开(公告)日：2010-02-25
申请号：KR1020100011765
申请日：2010-02-09
Applicant: (주)아모레퍼시픽
IPC: A61K36/14 , A61K36/254 , A61K36/74 , A61P17/00
Abstract: PURPOSE: A skin external composition containing herb extract is provided to suppress T lymphocyte-mediated immune reaction and treat or prevent dermatitis such as atopic dermatitis, contact dermatitis and prsoriasis. CONSTITUTION: A cosmetic composition for treating T-lymphocyte-mediated dermatitis contains 0.001-10 weight% of Thujae Semen extract as an active ingredient. The cosmetic composition is used in the form of massage cream, moisturizing cream, pack, gel, essence, lotion, ointment, gel, cream, or patch.
Abstract translation: 目的：提供含有草本提取物的皮肤外用组合物，以抑制T淋巴细胞介导的免疫反应，治疗或预防皮炎如特应性皮炎，接触性皮炎和牛皮癣。 构成：用于治疗T淋巴细胞介导的皮炎的化妆品组合物含有0.001-10重量％的Thujae Semen提取物作为活性成分。 化妆品组合物以按摩霜，保湿霜，包装，凝胶，精华液，洗剂，软膏，凝胶，霜或贴剂的形式使用。
-
公开(公告)号：KR1020090115705A
公开(公告)日：2009-11-05
申请号：KR1020090101103
申请日：2009-10-23
Applicant: (주)아모레퍼시픽
IPC: A61K36/185 , A61P17/06 , A61P17/00
Abstract: PURPOSE: A skin external composition containing medicinal herb extract is provided to ensure high suppression activity of immune reaction and prevent and treat dermatitis such as atopic dermatitis, contact dermatitis, and psoriasis. CONSTITUTION: A skin external composition for preventing or treating atopic dermatitis, contact dermatitis, or psoriasis contains medicinal herb extract as an active ingredient. The medicinal herb contains Asiasari Radix, Perillae Herba, Perillae Semen, Cimicifugae Rhizoma, Melandrii Herba, Solani Nigri Herba, Arctii Semen, Potentillae Radix, Cinnamomi Cortex Spissus, Hoelen rubra, Phaseoli angularis Semen, Fagopyrum esculentum, or Chenopodium album var. centrorubrum.
Abstract translation: 目的：提供含有药草提取物的皮肤外用组合物，以确保免疫反应的高度抑制活性，预防和治疗皮炎如特应性皮炎，接触性皮炎和牛皮癣。 构成：用于预防或治疗特应性皮炎，接触性皮炎或牛皮癣的皮肤外用组合物含有草药提取物作为活性成分。 药用草药含有Asiasari Radix，Perillae Herba，Perillae Semen，Cimicifugae Rhizoma，Melandrii Herba，Solani Nigri Herba，Arctii Semen，Potentillae Radix，Cinnamomi Cortex Spissus，Hoelen rubra，Phaseoli angularis Semen，Fagopyrum esculentum或Chenopodium album var。 centrorubrum。
-
公开(公告)号：KR1020080050786A
公开(公告)日：2008-06-10
申请号：KR1020060121508
申请日：2006-12-04
Applicant: (주)아모레퍼시픽
IPC: A61K31/133
Abstract: A method for inducing itch and a method for screening an itch inhibiting material using glucosylsphingosine are provided to be useful for studying and understanding the itch, thereby being very usefully used for developing a therapeutic agent for the itch and evaluating the effect of a medicine. A method for inducing itch comprises a step of administering at least one compound selected from the group consisting of glucosylsphingosine and a derivative thereof into an animal except human. A method for screening an itch inhibiting material comprises the steps of: (a) administering an itch inhibition candidate material to an animal where the itch is induced by administering at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof; and (b) counting a number when the animal scratches. A method for evaluating the itch inhibition effect comprises the steps of: (a) administering an itch inhibition material to an animal where the itch is induced by administering at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof; and (b) counting a number when the animal scratches. A composition for inducing itch comprises at least one compound selected from the group consisting of the glucosylsphingosine and the derivative thereof as an effective ingredient.
Abstract translation: 提供诱导瘙痒的方法和使用葡糖基鞘氨醇来筛选瘙痒抑制物质的方法，可用于研究和理解瘙痒，从而非常有用地用于开发瘙痒治疗剂并评估药物的效果。 诱导瘙痒的方法包括向除人之外的动物中施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物的步骤。 筛选瘙痒抑制物质的方法包括以下步骤：（a）通过施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物，向瘙痒诱导的动物施用瘙痒抑制候选物质; 和（b）当动物划伤时计数。 评估瘙痒抑制效果的方法包括以下步骤：（a）向通过施用至少一种选自葡糖基鞘氨醇及其衍生物的化合物诱导瘙痒的动物施用瘙痒抑制物质; 和（b）当动物划伤时计数。 用于诱导瘙痒的组合物包含至少一种选自葡糖基鞘氨醇及其衍生物的化合物作为有效成分。
-
公开(公告)号：KR1020080034575A
公开(公告)日：2008-04-22
申请号：KR1020060100703
申请日：2006-10-17
Applicant: (주)아모레퍼시픽
IPC: A61K31/047 , A61K31/13
CPC classification number: A61K31/047
Abstract: A method for inhibiting the expression of CCL27/CTACK(Cutaneous T-cell-attracting chemokine) is provided to regulate SPC(sphingosylphosphorylcholine) inducing expression of CCL27/CTACK, so that the method is useful for prevention and treatment of diseases associated with overexpression of CCL27/CTACK including atopic dermatitis, psoriasis and inflammatory skin disease. The expression of CCL27/CTACK is inhibited by administering an effective amount of sphingosylphosphorylcholine regulator capable of inhibiting activity of SPC or competing with the mechanism of SPC inducing overexpression of CCL27/CTACK to a mammal requiring the expression reduction of CCL27/CTACK. A method for screening the SPC regulator comprises the steps of: (1) treating a testing cell such as keratinocyte with 2-10 muM of SPC or its derivatives to induce overexpression of CCL27/CTACK; and (2) treating the overexpression of CCL27/CTACK-induced cell with a candidate material and measuring the expression inhibition of CCL27/CTACK. Further, the mammal has an atopic dermatitis or psoriasis.
Abstract translation: 提供抑制CCL27 / CTACK（皮肤T细胞吸引趋化因子）表达的方法，以调节诱导CCL27 / CTACK表达的SPC（鞘氨醇磷酰胆碱），从而该方法可用于预防和治疗与过表达相关的疾病 CCL27 / CTACK包括特应性皮炎，牛皮癣和炎性皮肤病。 通过施用有效量的能够抑制SPC活性或与诱导CCL27 / CTACK过表达的SPC的机制竞争需要CCL27 / CTACK表达降低的哺乳动物，CCL27 / CTACK的表达被抑制。 用于筛选SPC调节剂的方法包括以下步骤：（1）用2-10μM的SPC或其衍生物处理测试细胞如角质细胞，以诱导CCL27 / CTACK的过度表达; 和（2）用候选物质治疗CCL27 / CTACK诱导的细胞的过度表达，并测量CCL27 / CTACK的表达抑制。 此外，哺乳动物具有特应性皮炎或牛皮癣。
-
-
-
-
-
-
-
-
-
Search Results
55
records
(took 0.025 seconds)
